Oncomatryx

Oncomatryx is a global biopharmaceutical company headquartered in Zamudio, Spain. The company develops pioneering antibody-drug conjugates (ADCs), bispecific antibodies, and small molecules that target the tumor microenvironment of the most invasive solid tumors. Oncomatryx's lead drug candidate, OMTX705, is a first-in-class ADC that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. OMTX705 incorporates a cytolysin toxic payload developed by the acquired company Tube Pharmaceuticals GmbH. In preclinical studies, OMTX705 demonstrated complete tumor regression in pancreatic, breast, lung, and gastric cancer models and an unbeatable safety profile in rats and monkeys. In May 2022, the FDA and the Spanish Drug Agency cleared Oncomatryx's investigational new drug (IND) application for OMTX705. A phase I clinical trial evaluating OMTX705 as a single agent and in combination with immunotherapy is ongoing in metastatic solid tumor patients across seven hospitals in Spain and the US as of May 2023. In May 2023, Oncomatryx acquired Tube Pharmaceuticals GmbH, an Austrian company specializing in the development of novel ADC payloads, for an undisclosed multi-million-euro amount. The acquisition consolidated Oncomatryx's portfolio of cytolysins and ADC technology.